What is LOPJLB’s current signal on IMTX?

LOPJLB’s latest quantitative signal on Immatics N.V. (IMTX) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is IMTX in?

Immatics N.V. (IMTX) is currently classified in the CRISIS HMM market regime on LOPJLB.

Where is Immatics N.V. based / listed?

Immatics N.V. is based in DE, listed on NASDAQ.

Immatics N.V. (IMTX)

COMPARE

Healthcare · Biotechnology · NASDAQ · DE

$7.37-1.07%Close

SELLCRISIS · day 5

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $988M
Beta: 1.36
P/E (TTM): -4.19

Short % float: 3.96%
Days to cover: 8.3
SI change: -8.6%

1W: -12.68%
1M: -19.10%

vs SPY 1W: -14.24%
vs SPY 1M: -20.86%

Industry peers

FMP comparable companies · ranked by market cap

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid…

Employees: 704
Headquarters: DE
Founded: 2018
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 134.1M
Float: 83.7%

immatics.com ↗

Key executives

Harpreet Singh — Chief Executive Officer, MD, Member of Management Board & Executive Director

Carsten Reinhardt — Chief Development Officer

Hans-Georg Rammensee — Co-Founder & Member of the Scientific Advisory Board

SEC filings

EDGAR · CIK 18091960 · IMTX

Analyst consensus

Buy

Bullish8100.0%

Neutral00.0%

Bearish00.0%

L $17.00Avg $17.00H $17.00

Target$17.00+130.66%

Last$7.37

Key stats

Industry peers

Prediction markets

Company news